McKesson Declares Quarterly Dividend July 29, 2020

On July 29, 2020 The Board of Directors of McKesson Corporation (NYSE:MCK) reported a regular dividend of 42 cents per share of common stock (Press release, McKesson, JUL 29, 2020, View Source [SID1234562525]). The dividend will be payable on October 1, 2020, to stockholders of record on September 1, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout

On July 29, 2020 Amgen reported a bispecific drug it picked up in a $1.7 billion biobucks deal with Xencor (Press release, Amgen, JUL 29, 2020, View Source [SID1234562548]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In its second-quarter results, the biopharma said: "Phase 1 development of AMG 424, a CD38-CD3 XmAb antibody has been stopped, with rights reverting to Xencor."

Amgen nabbed the preclinical asset back in 2015 as part of an early-stage, bispecific six-drug development deal with Xencor. Under the deal, Amgen paid just $45 million upfront to use its R&D tech on some preclinical antibodies designed to harness the body’s natural defenses.

The pact was worth up to $1.7 billion in biobucks.
Xencor had been the biotech partner of choice for a number of Big Pharmas but was beginning to fall out of favor. In January last year, Novartis also returned the rights to a bispecific antibody it had licensed as part of a 2016 deal worth up to $2.41 billion.

A few months down the line, and the biotech was hit again after a second asset from that deal, in development for acute myeloid leukemia, hit a snag in the form of a partial clinical hold from the FDA. This came after a failed phase 2 test in lupus for the company in 2018.

But things had started to turn around: After working with Xencor to change the study protocol, the FDA lifted the partial clinical hold April 30.

And although Xencor lost Novartis as a partner on one of its programs, it picked up a new partner, licensing its preclinical-stage IL-15 cytokine therapeutics to Genentech for $120 million upfront in February last year.

Since then, Xencor has inked an R&D deal with Astellas and started phase 1 studies for two more bispecific antibodies in advanced solid tumors: XmAb2314, which targets PD-1 and ICOS, and XmAb22841, which targets CTLA-4 and LAG-3. The latter treatment is being tested in combination with Keytruda in an effort to block three checkpoints at once.

But the Amgen cull was still a hard hit for the biotech in the short term, with its shares off nearly 5% after-hours Tuesday on the news.

Meanwhile, one of the most keenly watched cancer drugs in development, KRAS drug AMG 510 (now known as sotorasib) is still on track to deliver data from a potentially pivotal phase 2 monotherapy study in patients with advanced non-small cell lung cancer (NSCLC) in the coming months, despite ongoing pandemic disruptions to trials.

Amgen also noted its phase 3 CodeBreaK 200 study comparing sotorasib to docetaxel is also now "enrolling patients with advanced NSCLC," while it has six phase 1 combination cohorts also enrolling.

Sales for Amgen grew 6% to $6.2 billion for the second quarter.

Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast

On July 29, 2020 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that the Company has scheduled the release of its second quarter 2020 financial results after the market closes on Wednesday, August 5, 2020 (Press release, Sangamo Therapeutics, JUL 29, 2020, View Source [SID1234562586]). The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 5667347. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 5667347.

Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020

On July 28, 2020 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that the Company will release its second quarter 2020 financial results on Tuesday, August 4, 2020, after the close of US markets (Press release, Curis, JUL 28, 2020, View Source [SID1234562435]). Management will host a conference call on the same day at 4:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the ‘Investors’ section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference

On July 28, 2020 Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, reported that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights and will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference (Press release, Epizyme, JUL 28, 2020, View Source [SID1234562462]). Details of both events are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Second Quarter 2020 Financial Results: Management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights on Tuesday, Aug. 4, 2020 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5081295.

2020 Wedbush PacGrow Healthcare Virtual Conference: Epizyme will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, Aug. 11, 2020, with a company overview to be presented at 9:45 a.m. ET.
Live webcasts will be available in the investor section of the company’s website at www.epizyme.com, and will be archived for 60 days following each event.